Drugdiscovery >> Drugs >> News
7023
Views
Velcade approved as a first line therapy in EU - drugdiscovery.com
Velcade approved as a first line therapy in EU - drugdiscovery.com


Johnson & Johnson's multiple myeloma treatment Velcade (bortezomib) has been used in advanced patients and those who were ineligible for stem cell transplantation. In the future, it will also be used as induction therapy in combination with dexamethasone and thalidomide in previously-untreated multiple myeloma patients who are eligible for high-dose chemotherapy and a stem cell transplant.
Read More >>


Tags: Velcade, multiple myeloma, Johnson & Johnson, approval, EC, EU - August 11, 2013
Related Articles
6208
Views
First biosimilar mAb therapy approved in Europe First biosimilar mAb therapy approved in Europe
Hospira’s Inflectra, monoclonal antibody (mAb) therapy, a biosimilar to Remicade (infliximab), has been approved by the European Commission (EC) for the treatment of inflammatory conditions includin Read More >>

Tags: Hospira, Inflectra, infliximab, Remicade, biosimilar, monoclonal antibody, inflamatory conditions, treatment, Europe

6119
Views
The first approved treatment for negative symptoms in schizophrenia to be launched in 2016 The first approved treatment for negative symptoms in schizophrenia to be launched in 2016
Roche/Chugai's glycine transporter-1 inhibitor bitopertin is poised to be the first-in-class agent for the treatment of negative symptoms in schizophrenia. The launch in the United States and Europe ( Read More >>

Tags: bitopertin, Roche, negative symptoms in schizophrenia, schizophrenia, symptoms, negative, new drug, new therapy

4481
Views
Avastin is not beneficial  as  front-line treatment of Glioblastoma Avastin is not beneficial as front-line treatment of Glioblastoma
New brain cancer studies suggest that Avastin does not prolong life when used as a first treatment for people with brain tumors and it Read More >>

Tags: Avastin, Brain tumor, Glioblastoma

5931
Views
Breakthrough Therapy Designation for Firdapse Breakthrough Therapy Designation for Firdapse
FDA has granted a Breakthrough Therapy Designation to Catalyst Pharmaceutical Partners for the drug Firdapse (amifampridine phosphate), for the symptomatic treatment of patients with Lambert-Eaton Mya Read More >>

Tags: Firdapse, Lambert-Eaton Myasthenic Syndrome, LEMS, orphan drug, breakthrough therapy

5172
Views
Two-drug therapy more effective than Enbrel monotherapy in RA Two-drug therapy more effective than Enbrel monotherapy in RA
According to a latest clinical trial, combined therapy of Enbrel (etanercept) and methotrexate in patients with rheumatoid arthritis (RA) is more effective than monotherapy with Enbrel. Read More >>

Tags: enbrel, etanercept, methotrexate, rheumatoid artritis, RA, monotherapy, two-drug therapy, clinical trial

3275
Views
Breakthrough Therapy designation for AML drug volasertib Breakthrough Therapy designation for AML drug volasertib
The FDA has granted Breakthrough Therapy designation to Boehringer Ingelheim’s investigational compound - volasertib, for the treatment of patients with acute myeloid leukemia. Read More >>

Tags: volasertib, acute myeloid leukemia, Boehringer Ingelheim, breakthrough therapy,experimental drug

15038
Views
How Drugs are Developed and Approved How Drugs are Developed and Approved
In the United States, all medications except natural remedies and supplements, must go through an approval process before they can be made available to people. The Food and Drug Administration (FDA) i Read More >>

Tags: FDA, CDER, drug safety

5446
Views
Breakthrough Therapy designation for leukemia drug Arzerra Breakthrough Therapy designation for leukemia drug Arzerra
The FDA has granted Breakthrough Therapy designation for the drug Arzerra (ofatumumab), co-development by Genamb and GSK, used in combination with chlorambucil for the treatment of patients with chro Read More >>

Tags: Arzerra, ofatumumab, chronic lymphocytic leukemia, CLL, breakthrough therapy designation

10647
Views
Another Sanofi MS drug approved in EU Another Sanofi MS drug approved in EU
After Aubagio, Lemtrada - another Sanofi’s drug for treatment of multiple sclerosis has been approved by the European Commission. Read More >>

Tags: multiple sclerosis, Europe, new drug, Aubagio, Lemtrada

6394
Views
Remicade Copies Approved in Europe Remicade Copies Approved in Europe
J&J’s Remicade, a drug for arthritis, will have cheaper versions made and sold by two other companies in Europe by 2014. Read More >>

Tags: Remicade, Arthritis, Celltrion, Hospira

MOST VIEWED
HOME | ABOUT | PRIVACY POLICY | TERMS & CONDITIONS | ADVERTISE | CONTACT
All rights reserved drugdiscovery.com 2013